

Application procedures for Therapeutic Use Exemptions (TUE)

Only *TUE* applications (and declarations of use) for players intending to participate in competitions of FIBA, as defined under article E.1 of the FIBA Internal Regulations governing the Competitions of FIBA, or in competitions of the Euroleague Basketball or EuroCup, are to be addressed to FIBA (regardless of whether the Player previously has received a TUE at national level).

The file must be filled in a LEGIBLE way, in either English or French, using the FIBA forms and must be addressed to FIBA as soon as possible and in any event (save in emergency situations) no later than 21 days before the first day of a FIBA Competition.

For any medical treatment requiring the use of a prohibited substance as defined in the List of the WADA Prohibited Substances and Methods and if there is no therapeutic alternative, the file will be studied by at least three doctors who are member of the FIBA *TUE* Committee (*TUEC*) and sent back to the applicant with an approval or refusal.

Specific medical conditions

- Application for the use of insulin in case of **diabetes**:
The TUE application form must be accompanied by a complete medical file from the player's physician.
- Application for the use of amphetamine in case of **ADHD** (Attention Deficit Hyperactivity Disorder):
A complete medical file must be provided containing the treatments during childhood, the current treatment and psychiatric examination.

Inhaled Beta-2 agonists and glucocorticosteroids (asthma)

- Players included in the *FIBA Registered Testing Pools* (RTP - Defined under the following link: <http://www.fiba.com/pages/eng/fc/expe/medi/antiDopi/p/openNodeIDs/1228/selectedNodeID/1228/registeredTestPool.html>) who intend to use *inhaled beta-2 agonists* (formoterol, salbutamol, salmeterol or terbutaline) in order to *treat asthma or one of its clinical variants* must obtain a TUE in advance of participating in a FIBA Competition.

The players also using inhaled *Glucocorticosteroids* shall declare it on the same TUE application form.

- Players not included in the FIBA RTPs may request a retroactive TUE for the above-mentioned substances only in case of an *Adverse Analytical Finding*.

Non-Inhaled, non-systemic Glucocorticosteroids (GCS)

- Players using GCS administered by non-systemic routes, namely intraarticular, periarticular, peritendinous, epidural, intradermal injections (and inhalation) must provide a *declaration of use*.
- For topical use of GCS, neither a TUE nor a declaration of use is requested.

Note: The TUE Rules are available under article I.4.4 of the FIBA Internal Regulations governing Anti-Doping and are in line with the WADA World Anti-Doping Code and the WADA International Standard for TUEs.